<DOC>
	<DOCNO>NCT00572559</DOCNO>
	<brief_summary>Ventilator-associated pneumonia ( VAP ) commonplace complication intensive care patient ventilate long 48 hour . Methicillin-resistant Staphylococcus aureus ( MRSA ) cause late onset VAP 30 % case US hospital . Ineffective treatment MRSA VAP clearly lead prolonged mechanical ventilation probably associate high mortality . The purpose protocol directly compare linezolid vancomycin specifically MRSA VAP .</brief_summary>
	<brief_title>Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>The patient must suspect ventilatorassociated pneumonia ( VAP ) due MRSA . Patient must hospitalize least 5 day , must ventilatordependent â‰¥ 48 hour prior screen/baseline , anticipated remain ventilator 72 hour enrollment followup BAL perform . Clinical picture compatible pneumonia ( acquire ventilation ) Chest X Ray baseline/screen within 24 hour initiation therapy must consistent diagnosis pneumonia Hypersensitivity linezolid , vancomycin , one excipients drug formulation . Infections due grampositive organism know resistant either study drug . Any antibiotic use treatment MRSA , vancomycin , TMP/SMX , rifampin , linezolid , 48 hour prior patient 's enrollment study . Patients neutropenia , AIDS , lymphoma anticipate chemotherapy . Patients longterm tracheostomy ( 60 day ) . Acute tracheostomy patient allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>